Back to Search
CRISTINA MENDIOLA, M.D.
M.D.
Obstetrics & Gynecology Physician
NPI: 1821264755Individual
Specialties, Licenses & Credentials
Obstetrics & Gynecology PhysicianPrimary
Obstetrics & Gynecology
Code: 207V00000X
265093(NY)
Research & Publications (13)
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
PMID 19661033·Clin Transl Oncol·2009
5-case
Negative prognostic impact of the coexpression of epidermal growth factor receptor and c-erbB-2 in locally advanced cervical cancer.
PMID 19174612·Oncology·2009
8-other
Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma.
PMID 18558584·Clin Transl Oncol·2008
8-other
Update in the management of ovarian and cervical carcinoma.
PMID 17652058·Clin Transl Oncol·2007
8-other
CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.
PMID 17237474·Ann Oncol·2007
2-rct
Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy.
PMID 17031408·Br J Cancer·2006
3-trial
It is not time to stop progesterone receptor testing in breast cancer.
PMID 15923595·J Clin Oncol·2005
8-other
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience.
PMID 15735115·J Clin Oncol·2005
3-trial
Body mass index as a prognostic feature in operable breast cancer: the International Breast Cancer Study Group experience.
PMID 15151943·Ann Oncol·2004
8-other
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
PMID 12751379·Eur J Cancer·2003
3-trial
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group.
PMID 12598351·Ann Oncol·2003
3-trial
High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.
PMID 11281378·Bone Marrow Transplant·2001
3-trial
Phase II trial of vinorelbine in patients with advanced and/or recurrent cervical carcinoma: an EORTC Gynaecological Cancer Cooperative Group Study.
PMID 10741277·Eur J Cancer·2000
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 355 W 52ND ST
NEW YORK, NY 10019 - Phone
- (646) 754-2100
Quick Facts
- NPI
- 1821264755
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 13
Are you this provider?
Claim Your Profile